Objective:To observe mutagenesis of retrovirus and adenovirus as transgenic vector,and provide safe clinic evidence for transgenic tumor cell as tumor vaccin.Methods:Cells were cultured together with virus.Then,DNA and supernatant were carried on an in vestigation in mutagenesis by means of laboratory technique about genetic toxicology.Results:The result indicated that DNA and supernatant of transgenic cell had no mutagenesis through test both In vivo and in vitroConclusion:The virus modified had no mutagenesis as transgenic vector.

Objective: To investigate the safety of transgenic human lung adenocarcinoma cell line SPC-A-1/IL-2 as tumor vaccine. Methods: IL-2 gene was introduced into human lung adenocarcinoma cell line SPC-A-1 and was expressed stably on the basis of the construction of retroviral packing cell line PA317/pLIL-2SN.The mutagenesis of both the DNA and supernatant of SPC-A-1/IL-2 in the and in vitro was tested by means of genetic toxicological techniques.Results:The result indicated that mutagenesis of both the DNA and the supernatant of transgenic cell SPC-A-1/IL-2 was not observed. Conclusion: The initial experiment suggested that the application of transgenic cell SPC-A-l/IL-2 as tumor vaccine was bisically safe and reliable.